Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | CFD | P00746 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29021152 | 0.98 | KDM4E (0.47) | KDM4EHSD17B10HTTTP53GAA | |
| SCHEMBL12012725 | 0.85 | KDM4E (0.41) | KDM4EHSD17B10HTTTP53GAA | |
| SCHEMBL3156904 | 0.82 | KDM4E (0.52) | KDM4EHSD17B10HTTTP53GAA | |
| SCHEMBL4764432 | 0.81 | CYP1A2 (0.40) | KDM4EHSD17B10HTTTP53GAA | |
| SCHEMBL23809728 | 0.80 | BACE1 (0.52) | KDM4EHSD17B10HTTTP53GAA | |
| SCHEMBL3600800 | 0.80 | HSD17B10 (0.55) | KDM4EHSD17B10HTTTP53GAA | |
| SCHEMBL4647729 | 0.80 | HSD17B10 (0.50) | KDM4EHSD17B10HTTTP53GAA | |
| SCHEMBL10790928 | 0.78 | HTT (0.49) | KDM4EHSD17B10HTTTP53GAA | |
| SCHEMBL7233258 | 0.78 | KDM4E (0.49) | KDM4EHSD17B10HTTTP53GAA | |
| SCHEMBL12299731 | 0.78 | KDM4E (0.49) | KDM4EHSD17B10HTTTP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117624131-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117624130-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-116323565-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-107266306-A | Process for preparing (2, 4-dimethylbiphenyl-3-yl) acetic acid, esters thereof and intermediate compounds | 拜耳知识产权有限责任公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-103980109-B | Process for preparing (2, 4-dimethylbiphenyl-3-yl) acetic acid, esters thereof and intermediate compounds | 拜尔农作物科学股份公司 | 2017-05-03 | — | — | CN | disclosed |
| US-7365209-B2 | Nitrogen heterocycle biaryls for osteoporosis and other diseases | PHARMACOPEIA, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365209-B2 | Nitrogen heterocycle biaryls for osteoporosis and other diseases | PHARMACOPEIA, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | PHARMACOPEIA, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | PHARMACOPEIA, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2007001249-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | PHARMACOPEIA, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | PHARMACOPEIA, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | PHARMACOPEIA, INC. (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | MSR1, EDNRA, GPR174 | KDM4E 2674/4885HSD17B10 2417/4885HTT 3577/4885 |
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | EDNRA, EDNRB, ESRRB | KDM4E 3106/4885HSD17B10 503/4885HTT 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.